Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy
Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential.
Vera Therapeutics Inc. (VERA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,300,000 | $148,428,000 | +11% | 2.6% |
| 2. | Kynam Capital Derrick Tang | 3,426,887 | $80,737,458 | +43% | 8.69% |
| 3. | Deerfield Management James E. Flynn | 3,348,117 | $78,881,637 | +219% | 1.43% |
| 4. | Vestal Point Capital Ryan Wilder | 3,100,000 | $73,036,000 | +24% | 3.85% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,608,372 | $61,453,244 | +161% | 0.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.35 | 27,071 | $605,082.87 | 3,596,593 | 2025-06-24 | Filing | |
| $22.35 | 13,536 | $302,552.61 | 1,797,619 | 2025-06-24 | Filing | |
| $20.87 | 139,595 | $2,913,110.34 | 3,569,522 | 2025-06-23 | Filing | |
| $20.87 | 69,798 | $1,456,565.60 | 1,784,083 | 2025-06-23 | Filing | |
| $31.00 | 161,290 | $4,999,990.00 | 3,628,446 | 2024-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.32 | 1,100 | $31,150.13 | 204,665 | 2025-02-26 | Filing | |
| $27.55 | 7,975 | $219,731.99 | 205,765 | 2025-02-26 | Filing | |
| $27.89 | 10,613 | $296,031.59 | 213,740 | 2025-02-21 | Filing | |
| $42.00 | 1,875 | $78,750.00 | 143,603 | 2025-01-08 | Filing | |
| $42.03 | 5,650 | $237,488.71 | 143,603 | 2025-01-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,165,540 | $98,140,122 | 0% | |
| 2. | 3,001,108 | $70,706,104 | 0% | |
| 3. | 2,909,964 | $68,558,751 | 0% | |
| 4. | 2,793,987 | $65,826,334 | 4.03% | |
| 5. | 2,238,252 | $52,733,229 | 0% |
News See All
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
Scotiabank Increases the Price Target for Vera Therapeutics by $10
The analyst informs investors that the business recently released positive topline data from the phase 3 ORIGIN study of atacicept, which showed that treatment with atacicept reduced proteinuria by 42...
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
10 Best Performing Small-Cap Stocks in 2024
The recent Fed rate cut has made the market cautiously optimistic. Despite the unusual timing, historical data suggests a continued upward trend. Recently, we discussed the Dow's new all-time high.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Hedge Fund and Insider Trading News: Crispin Odey, Starboard Value, Tiger Management, DiaMedica Therapeutics Inc (DMAC), Asana, Inc. (ASAN), and More
Crispin Odey, on paper, is a billionaire — commanding a vast wealth built over decades that’s unlikely to unravel as fast as his tenure atop Odey Asset Management.